Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remsima switch study in stable remission CD, UC, or RA
NL-OMON43846Phase 4Active, not recruiting
- Sponsor
- Mundipharma
- Start
- Jun 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of infliximab in Crohn's disease, autoimmune colitis and rheumatoid arthritis (RA), sponsored by Mundipharma. Started Jun 2015; status: active, not recruiting.
02
Drugs
infliximab
03
Conditions
Crohn's diseaseautoimmune colitisrheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON43846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43846.